.Pharmacolibrary.Drugs.ATC.L.L02BB06 .Pharmacolibrary.Drugs.ATC.L.L02BB06| name: | Darolutamide | |
| ATC code: | L02BB06 | route: | oral |
| compartments: | 2 | |
| dosage: | 600 | mg |
| volume of distribution: | 119 | L |
| clearance: | 116 | L/h |
| other parameters in model implementation | ||
Darolutamide is a nonsteroidal androgen receptor antagonist used to treat non-metastatic castration-resistant prostate cancer. It is an approved oral medication and is currently used in clinical settings.
Pharmacokinetic parameters reported for adult male patients with non-metastatic castration-resistant prostate cancer following oral administration of darolutamide 600 mg twice daily under fed condition.
Leblanc, K, et al., & Emmenegger, U (2024). Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus. Cancers 16(19) –. DOI:10.3390/cancers16193336 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39409956